Compendium of Cancer Genome Aberrations

Volunteer Assignments and Opportunities: Difference between revisions

← Older editNewer edit →
VisualWikitext
No edit summary
Snehal.Patel (talk | contribs)
editor
270 edits
No edit summary
(26 intermediate revisions by 5 users not shown)
Line 1: Line 1:
Welcome!  For assignments, please see the "Author" column below.  If no name is present, volunteer to create content!


To volunteer, please contact the Associate Editor helping with your page of interest (email can be found on the <u>[[Leadership]]</u> page).
{| class="wikitable"
{| class="wikitable"
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
Line 19: Line 17:
|
|
|Fabiola Quintero-Rivera (FQR)
|Fabiola Quintero-Rivera (FQR)
|Date page was created
|
|
|
|-
|-
Line 29: Line 27:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 39: Line 37:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 63: Line 61:
|-
|-
|    Essential  Thrombocythaemia (ET)||Disease
|    Essential  Thrombocythaemia (ET)||Disease
|Rebecca Smith
|Rebecca Smith (trainee) + Fabiola Quintero-Rivera
|
|
|
|
|complete
|complete/pending faculty review
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|Chelsea D. Kramish (trainee), Daynna J.Wolff
|(trainee), Daynna J.Wolff
|
|
|
|
|complete/pending faculty review
|pending faculty review
|
|
|FQR
|FQR
Line 84: Line 82:
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|Thomas Lee
|Thomas Lee
|
|8/17/2020
|
|9/7/2020
|complete
|complete
|
|
Line 92: Line 90:
|
|
|-
|-
|'''''Mastocytosis'''''||'''''Overview'''''||Shashi Shetty, Ph.D.
|'''''Mastocytosis'''''||'''''Overview'''''||'''Shashi Shetty, Ph.D.'''
|
|
|
|
Line 101: Line 99:
|-
|-
|    Cutaneous  Mastocytosis||Disease
|    Cutaneous  Mastocytosis||Disease
|Thuy Phung + Shuo-Shawn Liu (trainee)
|Thuy Phung/Shuo-Shawn Liu
|
|
|
|
|complete
|complete/pending adding content online as of 2/4/21
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Systemic Mastocytosis||Disease
|    Systemic Mastocytosis||Disease
Line 121: Line 119:
|-
|-
|    Mast Cell Sarcoma||Disease
|    Mast Cell Sarcoma||Disease
|Thuy Phung +Jordan Lowery (trainee)
|Thuy Phung +Jordan Lowery
|
|
|
|
Line 177: Line 175:
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff
|
|
|
|
Line 188: Line 186:
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee) + Daynna J. Wolff
|
|
|
|
Line 227: Line 225:
|
|
|9/1/20
|9/1/20
|PENDING reference formatting
|PENDING
|
|
|FQR
|FQR
Line 239: Line 237:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 289: Line 287:
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 299: Line 297:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 326: Line 324:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 470: Line 468:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg r
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health)
Conboy (Monash Health)
|
|
|
|
Line 479: Line 476:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health)
|
|
|
|
Line 760: Line 757:
|
|
|-
|-
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain + Yassmine Akkari
|
|
|
|
Line 832: Line 829:
|
|
|
|
|Complete
|PENDING
| ||YA
| ||YA
|
|
Line 951: Line 948:
|
|
|-
|-
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Jamie Nagy
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
|10/25/21
|
|
|
|
|PENDING
|
|
|SP
|SP
Line 960: Line 957:
|
|
|-
|-
|       Monoclonal B-cell  Lymphocytosis||Disease||Jamie Nagy
|       Monoclonal B-cell  Lymphocytosis||Disease||
|10/25/21
|
|
|
|
|PENDING
|
|
|SP
|SP
Line 1,150: Line 1,147:
|
|
|-
|-
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|8/31/2021
|
|9/15/2021
|
|PENDING
|
| ||SP
| ||SP
|
|
|
|
Line 1,174: Line 1,171:
|
|
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid  Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid  Tissue (MALT Lymphoma)||Disease||Whayoung Lee, trainee)/Fabiola Quintero-Rivera
|3/9/21
|3/9/21
|
|
Line 1,313: Line 1,310:
|
|
|-
|-
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||Laveniya Satgunaseelan
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
|26/10/2021
|
|26/1/2022
|
|Pending
|
| ||GC
| ||GC
|
|
Line 1,385: Line 1,382:
|
|
|-
|-
|ALK-Positive Large B-cell Lymphoma||Disease||Nakasaki, Manando(trainee)+ Fabiola Quintero-Rivera
|ALK-Positive Large B-cell Lymphoma||Disease||
|6/1/21
|
|
|
|
|pending
| ||GC
| ||GC
|
|
Line 1,417: Line 1,414:
|
|
|-
|-
|   Multicentric Castleman  Disease||Disease||Sudha Arumugam
|   Multicentric Castleman  Disease||Disease||
|10/26/2021
|
|1/26/2022
|
|Pending
|
| ||GC
| ||GC
|
|
|
|
|-
|-
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Sudha Arumugam
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|10/26/2021
|
|1/26/2022
|
|Pending
|
| ||GC
| ||GC
|
|
|
|
|-
|-
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||Sudha Arumugam
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
|10/26/2021
|
|1/26/2022
|
|Pending
|
| ||GC
| ||GC
|
|
Line 1,443: Line 1,440:
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|3/11/21
|3/11/21
|06/28/2021
|
|Complete
|PENDING
|28/06/2021||GC
| ||GC
|28/06/2021
|
|
|
|-
|-
|Burkitt-Like Lymphoma with 11q Aberration||Disease||Lauren Shealy (trainee), Daynna Wolff
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
|10/13/21
|
|
|
|
|Pending
| ||GC
| ||GC
|
|
Line 1,465: Line 1,462:
|
|
|-
|-
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||Kate Berry, Greg Corboy
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
|30/05/21
|
|30/08/21
|Pending
| ||GC
|
|
|
|
|-
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||Aiko Otsubo, Holli Drendel
|7/30/21
|10/30/21
|Pending
| ||GC
| ||GC
|
|
|
|
|-
|-
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
|    High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|
|
|
|
Line 1,489: Line 1,478:
|
|
|-
|-
| || ||
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
|
|
|
| ||GC
|
|
|-
| || ||
|
|
|
|
Line 1,687: Line 1,684:
|
|
|-
|-
|    Primary Cutaneous  Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD
|    Primary Cutaneous  Anaplastic Large Cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,959: Line 1,956:
|
|
|-
|-
|Histiocytic Sarcoma||Disease||Marie-France Gagnon, MD, Mayo Clinic (LGG fellow trainee), Xinjie Xu, PhD FACMG, Mayo Clinic
|Histiocytic Sarcoma||Disease||
|
|
|
| ||GC
|
|
|
|
|Complete
|10/01/2021
|GC
|10/01/2021
|Xinjie Xu
|-
|-
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
Line 1,976: Line 1,972:
|
|
|-
|-
|   Langerhans Cell  Histiocytosis||Disease||Prashant Deshpande
|   Langerhans Cell  Histiocytosis||Disease||
|10/26/2021
|
|1/26/2022
|
|Pending
|
| ||GC
| ||GC
|
|
|
|
|-
|-
|   Langerhans Cell  Sarcoma||Disease||Prashant Deshpande
|   Langerhans Cell  Sarcoma||Disease||
|10/26/2021
|
|1/26/2022
|
|Pending
|
| ||GC
| ||GC
|
|
Line 2,040: Line 2,036:
|
|
|-
|-
|Erdheim-Chester Disease||Disease||Prashant Deshpande
|Erdheim-Chester Disease||Disease||
|10/26/2021
|
|1/26/2022
|
|Pending
|
| ||GC
| ||GC
|
|
Line 2,208: Line 2,204:
|
|
|}
|}
{| class="wikitable"
|+WHO Classification of Tumours of the Central Nervous System Content
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|'''''Medulloblastoma, WNT-activated'''''||'''''Disease'''''||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|9/20/21
|
|
|
|
|
|
|-
|}
{| class="wikitable sortable"
{| class="wikitable sortable"
|+Gene-Specific Pages
|+Gene-Specific Pages
Retrieved from "https://content.ccga.io/index.php/Volunteer_Assignments_and_Opportunities"